Publications

Susan Guzman · Natalie Bellini · Lucille Hughes · Pasha Javadi ·Camilla Schanche · Maria Muccioli · Lori Berard Received: December 1, 2025 / Accepted: January 12, 2026 © The Author(s) 2026 Abstract Introduction: Effective insulin therapy relies on proper injection technique and the correct use of insulin delivery devices. Despite recommendations for a single-use device, the pen needle reuse

Korey K Hood, William H Polonsky Abstract Barriers to insulin therapy remain a critical challenge for individuals with insulin-treated diabetes, contributing to suboptimal clinical outcomes. The Afrezza® inhaled insulin system, with Technosphere® insulin (TI), is a promising alternative to subcutaneous insulin injections, offering a rapid pharmacokinetic profile and ease of use. Clinical studies demonstrate comparable HbA1c reductions, fewer hypoglycemic events, and

Authors: Emily C. Soriano, William Polonsky, Taylor L. Clark, Mariya Chichmarenko, Haley Sandoval, Alessandra Bastian, Addie L. Fortmann , Andrew Kwist, Fleur Levrat-Guillen Abstract OBJECTIVE Continuous glucose monitoring (CGM) improves type 2 diabetes (T2D) outcomes, but how this is achieved remains unclear. We explored how CGM affects diabetes-related attitudes and behavior, and whether these changes are associated with engagement in self-management

Authors: William H Polonsky, Emily C Soriano, Fleur Levrat-Guillen, Mariya Chichmarenko, Haley Sandoval, Alessandra Bastian, Addie L Fortmann, Andrew Kwist, Michael Vallis Abstract Background: Continuous glucose monitoring (CGM) promotes glycemic benefits in adults with type 2 diabetes (T2D), including insulin users as well as noninsulin users, often with minimal professional support. To investigate whether these benefits may stem from increased user engagement in self-management, we conducted a randomized controlled

Authors: Sufyan Hussain, William Polonsky,  Renza Scibilia, Timor Glatzer  Abstract Advances in diabetes technologies such as continuous glucose monitoring (CGM) have provided significant opportunities to improve glycemic and quality-of-life outcomes for people with type 1 diabetes (T1D). The ambulatory glucose profile and the introduction of glucose thresholds helped a lot to identify patterns, which was the first step toward improving hyper-and hypoglycemia

Authors: Danielle M Hessler, William H Polonsky, Lisa Strycker, Diana Naranjo, Katherine Greenberg, Lawrence Fisher Abstract Aims: To document stability and change over time, define a minimal clinically important difference (MCID), and examine the predictive validity of the new Type 1 Diabetes Distress Assessment System (T1-DDAS). Methods: A total of 574 adults with type 1 diabetes recruited through national registries and previous studies completed the T1-DDAS Core

Authors: Tuğba Bi Lgehan, Elif Gencer Şendur, Özlem Canbolat, Emre Dünder, William H Polonsky Abstract Aims: This study aimed to examine the psychometric properties of the Turkish version of the Type 1 Diabetes Distress Scale METHODS: This methodological, descriptive, and correlational study was conducted with 292 individuals diagnosed with Type 1 diabetes. Data were collected between January 2024 and August 2024 using the “Information Form

Authors: Lawrence Fisher, Susan Guzman, William H Polonsky, Lisa Strycker, Katherine Greenberg, Danielle M Hessler Abstract Objective: To document the effectiveness of diabetes distress (DD) interventions and to suggest how the improvements in DD, documented in a previous report, led to improved glycemic outcomes. Methods: Individuals with T1D (n = 276) with elevated DD (>2 on T1 Diabetes Distress Scale) and HbA1c (>7.5 %) were assigned to:

Authors: Viral N Shah, Terry Dex, Luigi Meneghini, Amélie Rodrigues, William H Polonsky Abstract Aims: In Soli-CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin-naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%-13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy) increased time in range (TIR; primary

Authors: Marisa Kostiuk, E Seth Kramer, Andrea Nederveld, Danielle M Hessler, Lawrence Fisher, Jessica A Parascando, Tamara K Oser Abstract Purpose of review: Addressing diabetes distress (DD), the emotional demands of living with diabetes, is a crucial component of diabetes care. Most individuals with type 2 diabetes and approximately half of adults with type 1 diabetes receive their care in the